Ardsley Advisory Partners’s ProShares UltraShort NASDAQ Biotechnology BIS Stock Holding History

Ardsley Advisory Partners’s Portfolio BIS Stock Details BIS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-55,000	Closed	-$19.2M	–	157
2016 Q1	$19.2M	Buy	55,000 +45,625	+487%	+$15.9M	2.96%	7
2015 Q4	$2.15M	Sell	9,375 -31,031	-77%	-$7.98M	0.28%	55
2015 Q3	$12.5M	Buy	40,406 +39,468	+4,208%	+$9.31M	3.02%	9
2015 Q2	$209K	Buy	+938	New	+$233K	0.03%	146

Other funds holding BIS

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

CMT Trading Chicago, Illinois $22.4M AUM 78.15% 1-Year Est. Return

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Ardsley Advisory Partners's BIS Position: Q2 2016 in Review

Ardsley Advisory Partners sold out of ProShares UltraShort NASDAQ Biotechnology (BIS) in Q2 2016, closing a stake of 55,000 shares — an estimated $19.2M sold.

Ardsley Advisory Partners first reported a position in BIS in Q2 2015 and held it in 4 quarters. The position peaked at $19.2M in Q1 2016. 14 funds tracked by Wall St. Rank hold BIS as of Q2 2016.

Ardsley Advisory Partners reported no remaining ProShares UltraShort NASDAQ Biotechnology position as of Q2 2016 after selling out during the quarter.
Ardsley Advisory Partners sold 55,000 ProShares UltraShort NASDAQ Biotechnology shares in Q2 2016, an estimated $19.2M.
Ardsley Advisory Partners first reported a position in ProShares UltraShort NASDAQ Biotechnology in Q2 2015 and held it in 4 quarters.
Ardsley Advisory Partners's ProShares UltraShort NASDAQ Biotechnology position peaked at $19.2M in Q1 2016.
14 funds tracked by Wall St. Rank held ProShares UltraShort NASDAQ Biotechnology as of Q2 2016.

Based on Ardsley Advisory Partners's 13F filing for Q2 2016, filed 15 Aug 2016.